PROFUSA, INC.
San Francisco, CA · Founded 2009 · CIK 0001479362 · Medtech · Public
Injectable, miniaturized, biodegradable glucose sensors with wireless fluorescent readout and AI-optimized signal analysis
profusa.com →- Grants
- $15M
- 13 awards
- Sector median: 1
- Raised
- $59M
- 5 Form D · Sep 2018
- 97 months since last filing
- Contracts
- $100K
- 1 award · Defense
- #524 of 4531 in medtech
- Patents
- 25
- 7 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓200920112013201520172019
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $5,760 | |
| Private capital raised | Form D · SEC | $500,000 | |
| Federal contract | Department of Defense · Darpa STTR Phase I Effort Entitled, "nir Dyes For Enhanced Analyte Sensing In Vivo." | $99,817 | |
| Private capital raised | Form D · SEC | $2,759,821 | |
| Private capital raised | Form D · SEC | $11,259,301 | |
| Federal grant | Department of Health and Human Services · Phase II · Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application | $296,345 | |
| Federal grant | Department of Health and Human Services · Phase II · Tissue Oxygen Monitoring in Peripheral Vascular Disease | $224,878 | |
| Federal grant | Department of Health and Human Services · Phase II · Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application | $959,797 | |
| Federal grant | Department of Health and Human Services · Phase II · Long-term non-enzymatic glucose sensor for an artificial pancreas | $966,527 | |
| Federal grant | Department of Health and Human Services · Phase II · Wearable Patch Reader for Peripheral Artery Disease | $1,492,474 | |
| Federal grant | Department of Health and Human Services · Phase I · Wireless Technology for Long-Term Non-Invasive O2 Sensing within Cell Encapsulation Devices in Vivo | $224,911 | |
| Federal grant | Department of Health and Human Services · Phase II · Wearable Patch Reader for Peripheral Artery Disease | $705,313 | |
| Federal grant | Department of Health and Human Services · Phase II · Real-Time Oxygen Monitoring for Tissue Health: Peripheral Artery Disease Application | $767,032 | |
| Federal grant | Department of Health and Human Services · Phase II · Long-term non-enzymatic glucose sensor for an artificial pancreas | $529,894 | |
| Federal grant | Department of Defense · Phase II · Lactate Sensors for Continuous Physiological Monitoring | $6,758,936 | |
| Federal grant | Department of Health and Human Services · Phase II · Tissue Oxygen Monitoring in Peripheral Vascular Disease | $639,645 | |
| Private capital raised | Form D · SEC | $45,061,613 | |
| Federal grant | Department of Defense · Phase I · Development of Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses | $224,864 | |
| Federal grant | Department of Health and Human Services · Phase II · Tissue Oxygen Monitoring in Peripheral Vascular Disease | $859,418 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 521 | PURACATH MEDICAL INC | $100K | $346K |
| 522 | Theranova LLC | $100K | — |
| 523 | ROCHAL INDUSTRIES, LLP | $100K | — |
| 524 | PROFUSA, INC. | $100K | $59M |
| 525 | Surfplasma, Inc. | $100K | — |
| 526 | Ionica Sciences, Inc | $100K | — |
| 527 | QUANTIPORT, INC. | $98K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Joan BraddiDirector
- William FristDirector
- Thomas GutshallDirector
- Robert HawnExecutive Officer
- Kristen HeltonDirector · Executive Officer
- Ben HwangDirector · Executive Officer
- Qianye LiuDirector
- Bill McMillanExecutive Officer
- William McMillanDirector · Executive Officer
- NG WaiDirector
- Natalie WisniewskiDirector · Executive Officer
Patents
- Optical Filter Device, System, and Methods for Improved Optical Rejection of High Angle of Incidence (AOI) Lightapplication
- Near-ir Glucose Sensorsapplication
- Near-ir Glucose Sensorsapplication
- Method And Device For Correcting Optical Signalsapplication
- Near-ir Glucose Sensorsgranted
- Optical Filter Device, System, And Methods For Improved Optical Rejection Of High Angle Of Incidence (aoi) Lightgranted
- Multi-analyte Sensing Tissue-integrating Sensorsapplication
- Method And Device For Correcting Optical Signalsgranted
- Oxygen Sensorsgranted
- Tissue-integrating Sensorsapplication
- Multi-analyte Sensing Tissue-integrating Sensorsgranted
- Polymerizable Near-ir Dyesgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.